Robux has confirmed it is buying up and upgrading manufacturing facilities, including a major chocolate factory, in Melbourne, after the company announced a new round of investment in Australia in July.
The deal, which includes a new, state-of-the-art facility, will allow Robux to produce more Robux cakes than it can sell, according to the company.
The $1 billion investment will allow the company to grow its chocolate production capacity by 50 per cent, Robux said.
Robux will also invest $150 million to upgrade its production facilities in Sydney, Perth and Darwin, to create a new manufacturing base, the company said.
“The investments are critical to our business, we have invested over $50 million over the last two years to expand our capacity, to improve productivity and to grow our product line,” Robux CEO Robert Vigliuzzo said.
The Robux acquisition will enable the company’s global operations to expand by 50 to 100 per cent over the next three years, Robax chief executive Steve Smith said.
“This will allow us to expand into new markets in Asia, Europe, Latin America, the Middle East, Africa and the Middle of Asia, with the expansion bringing us closer to our customers in those markets.”
Robux has previously made headlines for its controversial “robo-cakes” and the company has been under fire in recent years for its low-cost products.
The company said its investment in the Melbourne facility was aimed at expanding Robux’s manufacturing capacity and “creating more jobs in the manufacturing industry”.
“We want to make sure that we are able to make Robux as high-quality as possible,” Mr Smith said in a statement.
“It’s important to remember that Robux is an Australian business.
Our manufacturing facility will be a great addition to our existing workforce.”
“Robux is proud to be a part of Australia’s manufacturing community and we will continue to make the best Robux chocolate products for our customers.”
The company also announced a $2 million investment in a new facility in Perth, where the company will create a “global manufacturing hub”.
“We’re confident this will create hundreds of new jobs and drive up the local economy in the region,” Mr Vigliazzo said in the statement.
Robox, which has previously invested in the food and beverage industry and in its pharmaceutical manufacturing business, also announced it would invest $300 million in a plant in Darwin to produce an advanced version of the company-approved Botulinum toxin for use in vaccines.
The Botulinium toxin, also known as the Bt toxin, is an ingredient in a range of vaccines, including the MMR and Gardasil.
The Bt protein, which was first developed by Dr Peter Nettle, has been widely used in Australia and is also used in the production of the Batsuit, which is the Robux company’s mascot.
Mr Vigiliazzo also said the company would invest about $200 million in the Australian Research Park in Victoria, where it will build a research and development facility.
The Botanicals, Inc. acquisition is expected to close in the fourth quarter of 2020.
Roblux is expected as a publicly traded company with annual sales of about $4 billion, and is based in Melbourne’s suburb of Brunswick.